Background. The obese patients have differences in body composition, drug distribution, and metabolism. Sugammadex at recovery in a dose of 2？mg？kg？1 of real body weight (RBW) can completely reverse the NMB block; in our study we investigated the safety and efficacy of Sugammadex dose based on their ideal body weight (IBW). Methods. 40 patients of both sexes undergoing laparoscopic bariatric surgery were enrolled divided into 2 groups according to the dose of Sugammadex: the first received a dose of 2？mg？kg？1 of IBW and the second received a dose of 2？mg？kg？1 of RBW. Both were anesthetized with doses calculated according to the IBW: fentanyl 2？μg？kg？1, propofol 3？mg？kg？1, rocuronium 0,6？mg？kg？1, oxygen, air, and desflurane (6–8%). Maintenance doses of rocuronium were 1/4 of the intubation dose. Sugammadex was administrated at recovery. Results. The durations of intubation and maintenance doses of rocuronium were similar in both groups. In IBW group, the / value of 0.9 was reached in 151？±？44 seconds and in 121？±？55 seconds in RBW group ( ). Discussion. Recovery times to / of 0.9 are surprisingly similar in both groups without observing any postoperative residual curarization. Conclusion. Sugammadex doses calculated according to the IBW are certainly safe for a rapid recovery and absence of PORC. 1. Introduction Sugammadex, a modified γ-cyclodextrin, has been recently introduced into clinical practice as a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block during general anaesthesia. Sugammadex forms a complex with the neuromuscular blocking agents (NMBAs) rocuronium or vecuronium. By forming complexes with these NMBAs, it reduces their ability to bind to nicotinic receptors at the neuromuscular junction. Upon injection of Sugammadex, any rocuronium or vecuronium molecules present in the plasma and at their sites of action are attracted to Sugammadex via lipophilic binds in a ratio of one Sugammadex molecule to one molecule of the NMBA [1–4]. This causes a concentration gradient and any remaining rocuronium or vecuronium molecules are attracted back into the plasma and become bound to free Sugammadex molecules [2, 3]. At recovery of train-of-four (TOF) Sugammadex can completely reverse the neuromuscular block in a dose of 2？mg？kg？1 of real body weight (RBW). Obesity does not affect the efficacy of Sugammadex in reversing rocuronium-induced neuromuscular block [5], but the majority of authors and the literature recommend Sugammadex dose to be calculated upon RBW. As the obese patients have a different drug
References
[1]
J. M. Adam, D. J. Bennett, A. Borm, et al., “Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocked rocuronium bromide: synthesis and structure-activity relationships,” Journal of Medicinal Chemistry, vol. 45, no. 9, pp. 1806–1816, 2002.
[2]
M. Naguib, “Sugammadex: another milestone in clinical neuromuscular pharmacology,” Anesthesia and Analgesia, vol. 104, no. 3, pp. 575–581, 2007.
[3]
A. Bom, M. Bradley, K. Cameron, et al., “A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host,” Angewandte Chemie—International Edition, vol. 41, no. 2, pp. 266–270, 2002.
[4]
Bridion, (Sugammadex) Summary of Product Characteristics available via the electronic Medicines Compendium, 2009.
[5]
L. P. H. Yang and S. J. Keam, “Sugammadex: a review of its use in anaesthetic practice,” Drugs, vol. 69, no. 7, pp. 919–942, 2009.
[6]
T. Fuchs-Buder, C. Claudius, L. T. Skovgaard, L. I. Eriksson, R. K. Mirakhur, and J. Viby-Mogensen, “Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision,” Acta Anaesthesiologica Scandinavica, vol. 51, no. 7, pp. 789–808, 2007.
[7]
B. M. Balsiger, M. M. Murr, J. L. Poggio, and M. G. Sarr, “Bariatric surgery: surgery for weight control in patients with morbid obesity,” Medical Clinics of North America, vol. 84, no. 2, pp. 477–489, 2000.
[8]
Y. Leykin, T. Pellis, M. Lucca, G. Lomangino, B. Marzano, and A. Gullo, “The pharmacodynamic effects of rocuronium when dosed according to real body weight or ideal body weight in morbidly obese patients,” Anesthesia and Analgesia, vol. 99, no. 4, pp. 1086–1089, 2004.
[9]
K. H. Stokholm, J. Brochner-Mortensen, and P. F. Hoilund-Carlsen, “Increased glomerular filtration rate and adrenocortical function in obese women,” International Journal of Obesity, vol. 4, no. 1, pp. 57–63, 1980.
[10]
D. R. Abernethy and D. J. Greenblatt, “Pharmacokinetics of drugs in obesity,” Clinical Pharmacokinetics, vol. 7, no. 2, pp. 108–124, 1982.
[11]
D. R. Abernethy, D. J. Greenblatt, and M. Divoll, “Alterations in drug distribution and clearance due to obesity,” Journal of Pharmacology and Experimental Therapeutics, vol. 217, no. 3, pp. 681–685, 1981.
[12]
D. R. Abernethy, D. J. Greenblatt, M. Divoll, and R. I. Shader, “Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen,” Journal of Laboratory and Clinical Medicine, vol. 101, no. 6, pp. 873–880, 1983.
[13]
G. Cheymol, “Clinical pharmacokinetics of drugs in obesity—an update,” Clinical Pharmacokinetics, vol. 25, no. 2, pp. 103–114, 1993.
[14]
V. Nigrovic and M. Banoub, “Onset of the nondepolarizing neuromuscular block in humans: quantitative aspects,” Anesthesia and Analgesia, vol. 76, no. 1, pp. 85–91, 1993.
[15]
M. Naguib and A. F. Kopman, “Low dose rocuronium for tracheal intubation,” Middle East Journal of Anesthesiology, vol. 17, pp. 193–204, 2003.
[16]
A. Banoub and V. Migrovic, “The apparent space of interaction of muscle relaxants with post-synaptic nicotine receptors: implication for the onset of neuromuscular block,” Anesthesia and Analgesia, vol. 787, article S18, 1994.
[17]
J. Ingrande and H. J. M. Lemmens, “Dose adjustment of anaesthetics in the morbidly obese,” The British Journal of Anaesthesia, vol. 105, supplement 1, pp. i16–i23, 2010.
[18]
H. D. de Boer, J. J. Driessen, M. A. E. Marcus, H. Kerkkamp, M. Heeringa, and M. Klimek, “Reversal of rocuronium-induced (1.2？mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study,” Anesthesiology, vol. 107, no. 2, pp. 239–244, 2007.
[19]
O. Epemolu, A. Bom, F. Hope, and R. Mason, “Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969,” Anesthesiology, vol. 99, no. 3, pp. 632–637, 2003.
[20]
S. B. Groudine, R. Soto, C. Lien, D. Drover, and K. Roberts, “A randomized, dose-finding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block,” Anesthesia and Analgesia, vol. 104, no. 3, pp. 555–562, 2007.
[21]
I. F. Sorgenfrei, K. Norrild, P. B. Larsen et al., “Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study,” Anesthesiology, vol. 104, no. 4, pp. 667–674, 2006.
[22]
R. K. Mirakhur, “Sugammadex in clinical practice,” Anaesthesia, vol. 64, no. 1, pp. 45–54, 2009.
[23]
D. J. Eleveld, K. Kuizenga, J. H. Proost, and J. M. K. H. Wierda, “A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex,” Anesthesia and Analgesia, vol. 104, no. 3, pp. 582–584, 2007.
[24]
L. Drobnik, H. J. Sparr, S. Th？rn et al., “A randomized simultaneous comparison of acceleromyography with a peripheral nerve stimulator for assessing reversal of rocuronium-induced neuromuscular blockade with sugammadex,” European Journal of Anaesthesiology, vol. 27, no. 10, pp. 866–873, 2010.
[25]
D. L. McDonagh, P. E. Benedict, A. L. Kovac et al., “Efficacy, safety, and pharmacokinetics of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in elderly patients,” Anesthesiology, vol. 114, no. 2, pp. 318–329, 2011.
